Antiplatelet drugs stop platelets clumping together to form a clot on a damaged artery wall. They are a different job from anticoagulants: antiplatelets guard the arteries — after a heart attack or a stent — while anticoagulants guard against clots forming in slow-moving blood, as in atrial fibrillation.
Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons